RedChip's  Instablog

Facebook accounts for one in every seven minutes spent online worldwide, and Twitter users send 500 million tweets a day.

With social media now an essential part of users' daily routines, a growing number of marketers are harnessing social media as an advertising platform. Market researcher BIA Kelsey predicts social media advertising revenues will grow from $4.6 billion in 2012 to $9.2 billion in 2016, a compound annual growth rate of nearly 19%.

One way for investors to play the boom in social media advertising is through IZEA (OTCQB: IZEA). IZEA is a pioneer of social media sponsorship (SMS), a fast-growing segment of the social media advertising market. IZEA's platforms take the concepts of product placement and endorsements commonly found in movies, TV and radio and apply them to social media, allowing a wide variety of social media publishers, from college students and stay-at-home moms to celebrities, an opportunity to monetize their content. In exchange, advertisers gain direct exposure to the publishers' network of readers and fans.

IZEA works with over 850,000 registered social media publishers, or "influencers," in 147 different countries. The Company has completed over three million social media sponsorships for customers ranging from small local businesses to Fortune 50 organizations and top-tier brands such as Coca-Cola, AT&T, Microsoft, Kraft, HP, LG, Audi, Volvo, Hilton, Walgreens, Hershey and Sony. IZEA generates more than 220 million monthly SMS impressions through its advertising platforms, which include:

SocialSpark: IZEA's premium blog marketing platform, SocialSpark, connects advertisers with blog publishers to create sponsored blog posts.

Sponsored Tweets: Marketers pay for Twitter campaigns on either a Cost Per Tweet or a Cost Per Click basis. Advertisers can hand-pick individual tweeters, including celebrities.

Staree: Advertising platform that allows top social influencers to post photos, videos, and updates to their favorite social networks, earning cash in the process.

The Company reported revenues of $3.9 million for the nine months ended September 30, 2012, up nearly 40% over the same period in 2011. The Company's gross profit margin has nearly doubled since IZEA's inception in 2006, reaching 59% in the third quarter of 2012. With a sales pipeline of $12 million, IZEA is positioned for solid growth in 2013 and beyond.

IZEA currently trades at a discount to its trailing 12-month sales, creating a strong profit opportunity for investors who build a position today. Don't miss out.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

The 2012 Nobel Prize in Physiology and Medicine was awarded to Shinya Yamanaka of Kyoto University in Japan and John Gurdon of the University of Cambridge in England. Dr. Yamanaka and Dr. Gurdon received the award "for the discovery that mature cells can be reprogrammed to become pluripotent," an important step in the widespread commercialization of stem cell therapies.

While many stem cell therapies are still in experimental stages, or too costly for mass adoption, ongoing advances in the space are prevalent. It's becoming widely accepted amongst medical researchers that stem cell therapies will soon be able to treat cancer, diabetes, neurological disorders, muscle damage, Parkinson's, cardiac failure, and many other diseases.

One company with a first-mover advantage in China's stem cell market is Cellular Biomedicine Group ("CBMG"). CBMG has successfully acquired, transferred, commercialized and advanced 30 years of research and human treatment experience in progenitor cells and cancer cell technology. The Company's cellular research and development is the result of collaboration between scientists and doctors from both the U.S. and China.

CBMG announced on Nov. 14, 2012 that it entered into an agreement to merge with EastBridge Investment Group Corp. (OTCQB: EBIG), a financial consulting firm focused on providing professional advice to small, high-growth companies seeking to access the U.S. capital markets. The merger is anticipated to complete in January 2013. The combined entity will operate in two segments, with EastBridge continuing its current operational focus as a division of the parent company.

CBMG scientists currently develop biomedicine based on tissue-derived progenitor (stem) cells, embryonic stem cells (ES), cytokine induced killer cells (CIK) and cancer-specific dendritic cells. The Company considers these types of cells as viable options for cell-based therapies that can be applied to a variety of medical indications. Ongoing research will determine the most effective applications for each type of cell.

The Company's technologies are founded on scientific innovations in the field of regenerative medicine. CBMG's IP portfolio of cellular biomedicine products target cancer, osteoarthritis, tissue damage as a result of stroke, spinal muscular atrophy, various inflammatory diseases, joint repair, metabolic diseases and ophthalmology diseases.

Investors have a lot of upside with CBMG. It has the right management and scientific team in place to move its robust product pipeline through to commercialization. As an added bonus, once the merger with EBIG is complete in January, the Company will have additional high-margin revenue generation from EBIG's core financial consulting business. This added cash flow will further support the Company's product development efforts.

To learn more about this exciting opportunity with China's stem cell leader, view CBMG's recent presentation from our December virtual conference or contact a specialist today at 1-407-644-4256, ext. 0.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.

Mobile app developer MEDL Mobile Holdings, Inc. (OTCBB: MEDL) achieved several major milestones in 2012, as CEO Andrew Maltin discussed during the recent RedChip Small-Cap Virtual Conference.

Over the past 12 months, MEDL grew total downloads to more than 18 million, grew total installations of its proprietary "Brain API" technology to more than 3.5 million, and doubled its current catalog to approximately 200 apps at almost no cost. MEDL also added many new celebrity app partnerships, supplementing its existing partnerships with celebrities such as Cheech & Chong, Rampage Jackson, and Pauly D.

During the online conference, Mr. Maltin provided an in-depth discussion of MEDL's new, proprietary "Hang w/" platform. MEDL developed Hang w/ in response to a problem consistently mentioned by its celebrity partners: Celebrities spend significant amounts of time and money building social media traffic, but they receive little or no revenue. Hang w/ solves this challenge by enabling celebrities to monetize their social media profiles while building engagement with fans.

Hang w/ is the first live mobile video broadcast service for celebrities and fans. The service lets celebrities stream live video from their phones directly to millions of fans, allowing fans to essentially "hang out" with their favorite celebrities. The Hang w/ platform generates revenue from advertisements that play immediately before and after fans view the live feed. MEDL's history of developing mobile apps for top-tier brands such as Taco Bell, Verizon, and Universal Pictures should help the Company secure branded sponsorships for the Hang w/ platform.

Unlike Google Hangouts or other popular celebrity streaming services such as Ustream, Hang w/ is the first platform designed to deliver and monetize a live celebrity video experience via mobile. MEDL successfully beta-tested Hang w/ in October at KCON, a large-scale convention focused on Korean entertainment. During the demo, MEDL streamed live content to thousands of users via the Hang w/ platform. The Company plans a soft launch of Hang w/ on New Year's Eve.

Hang w/ represents a significant opportunity for MEDL. The platform's market potential extends far beyond celebrities: Teachers, motivational speakers, health and fitness professionals, popular brands, YouTube "weblebrities," and faith-based groups are all potential users of Hang w/. MEDL's management team expects Hang w/ to generate revenues of $5 million and $45 million in its first and second years, respectively.

In anticipation of the Hang w/ launch, MEDL further solidified its seasoned management team with recent additions. The Company added Peter Elkin, a veteran deal maker with more than 25 years of business experience, to oversee the launch of Hang w/. Murray Williams, a founding member of Buy.com, also joined MEDL as chief financial officer. Mr. Williams served as Buy.com's CFO during a period in which the company sold over $1 billion in products. Buy.com was the fastest-growing company in the world, with sales of $125 million in its first year of operations.

According to Gartner, a technology-focused market research firm, global social media revenue is projected to reach $16.9 billion in 2012, up 43.1 percent from $11.8 billion in 2011. MEDL's revolutionary Hang w/ platform provides the Company with a strong advantage in social media as a first-mover in the mobile video market. With the critical elements for success in place, it's only a matter of time before MEDL shares begin trading significantly higher. Don't miss your opportunity to invest.

Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.